Phibro Animal Health CEO Executes Share Sale Amid Strong Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy PAHC?
Source: Fool
- Executive Share Sale: Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 14,080 shares of common stock through indirect open-market transactions on February 13 and 18, 2026, for total proceeds of approximately $728,000, indicating proactive management of executive holdings.
- Ownership Analysis: Post-transaction, Bendheim retains 16,840 shares directly and 36,680 shares indirectly, totaling 53,520 shares, suggesting a continued optimistic outlook on the company's future without an immediate rush to liquidate his holdings.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted in May 2025, aimed at avoiding insider trading allegations, highlighting the executive's commitment to transparency and compliance.
- Company Performance Highlights: Phibro reported a 21% year-over-year revenue increase in its fiscal Q2 2026, reaching $373.9 million, and raised its full-year revenue guidance to between $1.45 billion and $1.50 billion, reflecting strong performance in the animal health sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAHC
Wall Street analysts forecast PAHC stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 52.270
Low
45.00
Averages
47.50
High
50.00
Current: 52.270
Low
45.00
Averages
47.50
High
50.00
About PAHC
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phibro Animal Health CEO Executes Share Sale Amid Strong Performance
- Executive Share Sale: Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 14,080 shares of common stock through indirect open-market transactions on February 13 and 18, 2026, for total proceeds of approximately $728,000, indicating proactive management of executive holdings.
- Ownership Analysis: Post-transaction, Bendheim retains 16,840 shares directly and 36,680 shares indirectly, totaling 53,520 shares, suggesting a continued optimistic outlook on the company's future without an immediate rush to liquidate his holdings.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted in May 2025, aimed at avoiding insider trading allegations, highlighting the executive's commitment to transparency and compliance.
- Company Performance Highlights: Phibro reported a 21% year-over-year revenue increase in its fiscal Q2 2026, reaching $373.9 million, and raised its full-year revenue guidance to between $1.45 billion and $1.50 billion, reflecting strong performance in the animal health sector.
See More
Jack Bendheim's Executive Update
- Executive Leadership Update: Jack Bendheim continues to serve as the company's Director, President, and CEO as of February 24, 2026, holding a 10% ownership stake, reflecting his ongoing commitment and leadership.
- Governance Stability: Bendheim's continued role helps maintain governance stability, ensuring consistency in strategic direction, which in turn enhances investor confidence.
- Market Reaction Expectations: While specific financial data is not disclosed, Bendheim's leadership experience may positively impact the company's future market performance, especially in uncertain economic conditions.
- Strategic Development Potential: Under Bendheim's leadership, the company is poised to achieve strategic development goals, further enhancing its market competitiveness and business growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares in Open Market
- Executive Sale Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating sustained confidence in the company's stock despite the sale.
- Ownership Impact: The transaction resulted in approximately 51.64% of Bendheim's total holdings (both direct and indirect) being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting the executive's sensitivity to market dynamics.
- Transaction Context: This sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating a strategic approach to risk management amidst market fluctuations.
- Company Performance Outlook: Phibro's Q2 fiscal year 2026 earnings report showed year-over-year growth in revenue, net income, and earnings per share, with the CEO expressing confidence in future performance, particularly in the demand for its nutrition products and vaccines, which are expected to drive long-term growth.
See More
Phibro Animal Health CEO Sells 72,198 Shares After Strong Q2 2026 Performance
- Transaction Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating confidence in the company's future prospects.
- Ownership Impact: This transaction resulted in approximately 51.64% of Bendheim's total holdings being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting sensitivity to market dynamics.
- Trading Plan Context: The sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating that Bendheim's actions were not influenced by recent company news, thus maintaining transparency.
- Company Performance Highlights: Phibro reported year-over-year revenue growth in its Q2 2026 earnings, with net income reaching $92.09 million, underscoring strong demand for its animal nutrition products and vaccines, suggesting promising future growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares for $3.74 Million
- Executive Sell-Off: Jack Bendheim, President and CEO of Phibro Animal Health, sold 72,198 shares through an indirect entity, BFI Co. LLC, between February 10 and 11, 2026, for approximately $3.74 million at an average price of $51.77 per share, indicating a cautious stance on the company's future despite strong past performance.
- Stable Holdings: Despite the significant indirect sale, Bendheim's direct holdings remain unchanged at 16,840 shares, reflecting his confidence in the company's long-term prospects and a strategy that is not swayed by short-term market fluctuations.
- Positive Financial Performance: In its recent Q2 earnings report for fiscal year 2026, Phibro reported year-over-year growth in revenue, net income, and earnings per share, highlighting strong demand for its animal nutrition products and vaccines, which bolsters investor confidence in the company.
- Optimistic Market Outlook: With ongoing threats from diseases like avian influenza, Phibro's medicated feed additive portfolio is expected to continue growing, especially after acquiring over 37 product lines in late 2024, further solidifying its market position and addressing critical needs in the agricultural sector.
See More
Phibro Animal Health to Participate in 2026 Summit
- Executive Participation: Phibro Animal Health Corporation will participate in the Bank of America 2026 Virtual Animal Health Summit on February 26, 2026, where CFO Glenn David, COO Larry Miller, and CEO designate Daniel Bendheim will address financial analysts and investors, likely enhancing the company's visibility in the industry.
- Live and Archived Access: The live audio presentation will be available on Phibro's Investor Relations website, with a replay archived for later access, ensuring that investors unable to attend in real-time can still obtain relevant information, thereby increasing transparency and investor trust.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, committed to providing solutions that help livestock producers, farmers, and veterinarians maintain and enhance animal health, showcasing its expertise and market position in the animal health sector.
- Information Access Channels: The company offers multiple channels for investors to access information, including filings with the Securities and Exchange Commission and its website, ensuring that investors can stay updated on the latest developments and financial status, further enhancing communication with stakeholders.
See More
Phibro Animal Health CEO Executes Share Sale Amid Strong Performance
- Executive Share Sale: Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 14,080 shares of common stock through indirect open-market transactions on February 13 and 18, 2026, for total proceeds of approximately $728,000, indicating proactive management of executive holdings.
- Ownership Analysis: Post-transaction, Bendheim retains 16,840 shares directly and 36,680 shares indirectly, totaling 53,520 shares, suggesting a continued optimistic outlook on the company's future without an immediate rush to liquidate his holdings.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted in May 2025, aimed at avoiding insider trading allegations, highlighting the executive's commitment to transparency and compliance.
- Company Performance Highlights: Phibro reported a 21% year-over-year revenue increase in its fiscal Q2 2026, reaching $373.9 million, and raised its full-year revenue guidance to between $1.45 billion and $1.50 billion, reflecting strong performance in the animal health sector.
See More
Jack Bendheim's Executive Update
- Executive Leadership Update: Jack Bendheim continues to serve as the company's Director, President, and CEO as of February 24, 2026, holding a 10% ownership stake, reflecting his ongoing commitment and leadership.
- Governance Stability: Bendheim's continued role helps maintain governance stability, ensuring consistency in strategic direction, which in turn enhances investor confidence.
- Market Reaction Expectations: While specific financial data is not disclosed, Bendheim's leadership experience may positively impact the company's future market performance, especially in uncertain economic conditions.
- Strategic Development Potential: Under Bendheim's leadership, the company is poised to achieve strategic development goals, further enhancing its market competitiveness and business growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares in Open Market
- Executive Sale Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating sustained confidence in the company's stock despite the sale.
- Ownership Impact: The transaction resulted in approximately 51.64% of Bendheim's total holdings (both direct and indirect) being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting the executive's sensitivity to market dynamics.
- Transaction Context: This sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating a strategic approach to risk management amidst market fluctuations.
- Company Performance Outlook: Phibro's Q2 fiscal year 2026 earnings report showed year-over-year growth in revenue, net income, and earnings per share, with the CEO expressing confidence in future performance, particularly in the demand for its nutrition products and vaccines, which are expected to drive long-term growth.
See More
Phibro Animal Health CEO Sells 72,198 Shares After Strong Q2 2026 Performance
- Transaction Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating confidence in the company's future prospects.
- Ownership Impact: This transaction resulted in approximately 51.64% of Bendheim's total holdings being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting sensitivity to market dynamics.
- Trading Plan Context: The sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating that Bendheim's actions were not influenced by recent company news, thus maintaining transparency.
- Company Performance Highlights: Phibro reported year-over-year revenue growth in its Q2 2026 earnings, with net income reaching $92.09 million, underscoring strong demand for its animal nutrition products and vaccines, suggesting promising future growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares for $3.74 Million
- Executive Sell-Off: Jack Bendheim, President and CEO of Phibro Animal Health, sold 72,198 shares through an indirect entity, BFI Co. LLC, between February 10 and 11, 2026, for approximately $3.74 million at an average price of $51.77 per share, indicating a cautious stance on the company's future despite strong past performance.
- Stable Holdings: Despite the significant indirect sale, Bendheim's direct holdings remain unchanged at 16,840 shares, reflecting his confidence in the company's long-term prospects and a strategy that is not swayed by short-term market fluctuations.
- Positive Financial Performance: In its recent Q2 earnings report for fiscal year 2026, Phibro reported year-over-year growth in revenue, net income, and earnings per share, highlighting strong demand for its animal nutrition products and vaccines, which bolsters investor confidence in the company.
- Optimistic Market Outlook: With ongoing threats from diseases like avian influenza, Phibro's medicated feed additive portfolio is expected to continue growing, especially after acquiring over 37 product lines in late 2024, further solidifying its market position and addressing critical needs in the agricultural sector.
See More
Phibro Animal Health to Participate in 2026 Summit
- Executive Participation: Phibro Animal Health Corporation will participate in the Bank of America 2026 Virtual Animal Health Summit on February 26, 2026, where CFO Glenn David, COO Larry Miller, and CEO designate Daniel Bendheim will address financial analysts and investors, likely enhancing the company's visibility in the industry.
- Live and Archived Access: The live audio presentation will be available on Phibro's Investor Relations website, with a replay archived for later access, ensuring that investors unable to attend in real-time can still obtain relevant information, thereby increasing transparency and investor trust.
- Company Overview: Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company, committed to providing solutions that help livestock producers, farmers, and veterinarians maintain and enhance animal health, showcasing its expertise and market position in the animal health sector.
- Information Access Channels: The company offers multiple channels for investors to access information, including filings with the Securities and Exchange Commission and its website, ensuring that investors can stay updated on the latest developments and financial status, further enhancing communication with stakeholders.
See More
